SLN — Silence Therapeutics plc

Silence Therapeutics (SLN) Q4 2024 Earnings Call Summary

1. Key Financial Results and Metrics:

• Revenue: $43.3 million for FY 2024, up from $31.6 million in 2023, primarily due to collaboration agreements.
• Net Operating Loss: Approximately $63.3 million, slightly improved from $64.4 million in 2023.
• Net Loss: Approximately $45.3 million, down from $54.2 million in 2023.
• Cash Position: $147.3 million at year-end, consisting of $121.3 million in cash and cash equivalents and $26 million in short-term investments.
• R&D Expenses: Increased to $67.9 million from $56.9 million in 2023, reflecting investment in clinical programs.

2. Strategic Updates and Business Highlights:

• Zerlasiran: Positive Phase 2 results in ASCVD patients with high Lp(a) were presented at AHA and published in JAMA. The Phase 3 program is designed but will only commence once a partner is secured.
• Divesiran: Positive Phase 1 results for polycythemia vera (PV) were highlighted, with the Phase 2 study expected to fully enroll by year-end. Divesiran has received Orphan Drug Designation in Europe and FDA Fast Track designation.
• Pipeline Development: Initiated a new siRNA candidate, SLN548, targeting complement factor B, with a Phase 1 study planned for the second half of 2025.
• Collaboration Updates: The partnership with Hansoh Pharma ended, but Silence retains rights to three preclinical liver targets, which may be developed independently or partnered.

3. Forward Guidance and Outlook:

• The company is prioritizing investments in rare conditions with unmet needs, particularly focusing on divesiran and other promising siRNA therapies.
• The decision to delay the Phase 3 study for zerlasiran until a partner is secured extends the cash runway to 2027, allowing for continued investment in the pipeline.

4. Bad News, Challenges, or Points of Concern:

• The termination of the collaboration with Hansoh Pharma may limit potential revenue from those projects.
• The reliance on securing a partner for zerlasiran before initiating the Phase 3 trial introduces uncertainty and could delay development timelines.
• Competitive pressures in the cardiovascular space, particularly concerning Lp(a) treatments, may impact partnership discussions and market positioning.

5. Notable Q&A Insights:

• Management refrained from providing specifics on partnership discussions for zerlasiran but acknowledged increased interest in Lp(a) studies from other companies.
• Questions regarding the readiness for the Phase 3 trial indicated that logistical preparations are on track, with some flexibility remaining for adjustments with a potential partner.
• The differentiation of divesiran from competitors like rusfertide will focus on dosing frequency and overall patient outcomes, with ongoing evaluations for potential expansion into hereditary hemochromatosis.
• Management expressed confidence in the safety profile of divesiran, noting that the therapeutic approach of increasing endogenous hepcidin differs from exogenous treatments.

Overall, Silence Therapeutics is navigating a complex landscape with promising clinical data and strategic partnerships while facing challenges related to collaboration terminations and the need for external partnerships to advance key programs.